P573 Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive ulcerative colitis patients: Results from the EVOLVE study
Andrés Yarur(Cedars-Sinai Medical Center), Brian Bressler(University of British Columbia), Gerassimos J. Mantzaris(European CanCer Organisation), Petros Zezos(Mount Sinai Hospital), M Bassel, Margaret Walshe(Mount Sinai Hospital), Dirk Demuth(Takeda (Singapore)), Dan J. Stein(University of Cape Town), Haridarshan Patel(Amgen (United States)), T Lissoos(Takeda (United States)), Athanasios Natsios(Municipality of Athens Development Agency), Mark S. Silverberg(Sinai Health System), Claudia Lopez(Takeda (United States)), Gabriela Radulescu(Smithsonian Institution)
Cited by 8
Related Papers
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k